Skip to content
Peptide research

Liraglutide

Also known as Saxenda · Victoza
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

Liraglutide is a GLP-1 receptor agonist marketed for type 2 diabetes and weight loss. Human evidence here is genuinely strong, backed by large trials showing glycemic control, weight loss, and cardiovascular risk reduction. Tradeoffs include common GI side effects, gallbladder and pancreatitis risk, and a boxed thyroid tumor warning barring those with medullary thyroid cancer history. It is FDA-approved (Saxenda, Victoza), not a gray-market peptide.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Type 2 diabetes glycemic control

    High

    Large phase 3 trials showed HbA1c reductions of about 1 to 1.5 percentage points.

  • Significant weight loss

    High

    Large 56-week trial showed average weight loss of 8.4 kg versus 2.8 kg with placebo.

  • Cardiovascular risk reduction

    High

    Large cardiovascular outcomes trial in high-risk type 2 diabetes patients showed reduced major cardiac events.

Evidence limits

Evidence Level
Level 1 — Strong

Over 25,000 participants across Phase 3 programs (LEAD, SCALE, LEADER). Strong evidence for glycemic control, weight loss, CV risk reduction, and renal protection. 9,340-patient LEADER CVOT with 3.8-year follow-up is the cornerstone trial.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of MTC

    Absolute

    FDA boxed warning: thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.

  • History of pancreatitis

    High

    Post-marketing cases of acute pancreatitis including fatal hemorrhagic pancreatitis reported.

  • Severe gastroparesis

    High

    Slows gastric emptying. Patients with gastroparesis excluded from clinical trials.

  • Severe renal impairment

    Moderate

    GI side effects may cause dehydration and acute kidney injury. Monitor renal function.

General cautions

  • Pregnancy

    Absolute

    Animal studies indicate potential fetal harm. Discontinue Saxenda when pregnancy is recognized. FDA labeling does not specify a two-month preconception interval for liraglutide.

Risk summary(10)

Risks = level of concern: High · Moderate · Low · Theoretical

  • GI side effects: nausea, diarrhea, vomiting, decreased appetite, constipation (most common, affecting 20-40%)

    High
  • Hypoglycemia risk when combined with insulin or sulfonylureas; dose reduction of co-administered agents may be needed

    High
  • Gallbladder disease: cholelithiasis occurred in 2.2% versus 0.8% with placebo in Saxenda adult trials; cholecystitis occurred in 0.8% versus 0.4%. LEADER acute gallbladder events were 3.1% versus 1.9%.

    Moderate
  • Elevated resting heart rate: 4-9 bpm increase; reports of tachycardia >100 bpm

    Moderate
  • Boxed warning: thyroid C-cell tumors in rodent studies at clinically relevant doses; contraindicated in MTC/MEN 2 patients

    Moderate
  • Acute pancreatitis risk (<0.4% of patients); discontinue if suspected

    Moderate
  • Acute kidney injury: postmarketing reports, usually secondary to dehydration from GI effects

    Low
  • Historical reports of suicidal behavior and ideation prompted review, but FDA found no increased risk and the Saxenda warning was removed in February 2026.

    Theoretical
  • Hypersensitivity reactions: anaphylaxis and angioedema reported (rare)

    Low
  • Injection site reactions: erythema, pruritus, nodule formation

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.